ADC therapeutics receives FDA clearance to begin clinical studies for its second novel antibody drug conjugate ADCT-402 against lymphomas and leukemia

ADC Therapeutics SA, the oncology drug development company focused on Antibody Drug Conjugates (ADCs), today announced that it has received clearance from the US Food and Drug Administration (FDA)… Source link